drugset / Trial / NCT02677298

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

NCT02677298

Phase 3 Completed 784 enrolled Croma-Pharma GmbH
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.

Timeline

Start
2016-03-02
Primary completion
2016-11-23
Completion
2017-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject letibotulinumtoxinA Protein / enzyme biologic 20 iu Intramuscular

Indications

No indication recorded.